The warnings you remember on menopause hormone therapy have changed

Hot flashes are waking you up twice a night. A friend mentioned hormone therapy, and the first thing you remembered was the warning on the box. You're not alone in that. For years it was the first thing most people heard.

That warning has changed. It's worth knowing exactly how, because it changes the conversation you can have with your provider. It doesn't make the decision for you.

What the FDA changed

On November 10, 2025, the U.S. Department of Health and Human Services announced that the FDA was initiating the removal of broad boxed warnings from hormone therapy products for menopause. The statements in question covered cardiovascular disease, breast cancer and probable dementia.

On February 12, 2026, the FDA approved labeling changes to 6 menopausal hormone therapy products. In the agency's words, "risk statements related to cardiovascular disease, breast cancer and probable dementia were removed" from the boxed warning on those labels. The FDA said the change was meant to clarify risk considerations for these drugs.

What didn't change

Hormone therapy didn't become risk-free, and nobody claimed it did. The HHS announcement said the FDA isn't seeking to remove the boxed warning for endometrial cancer for systemic estrogen-alone products. Every product still carries its own label, with its own risks and the situations where it shouldn't be used.

The February approvals also covered the first 6 products, not every product on the market. If you're weighing a specific medicine, its current label is the one that applies.

Who the balance tends to favor

The Menopause Society sets out its view in its 2022 hormone therapy position statement, published under the name The North American Menopause Society and still listed on its website. For women younger than 60 or within 10 years of menopause onset, with no contraindications, the statement concludes that "the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss." VMS means vasomotor symptoms, the hot flashes and night sweats most people know.

Read that carefully, because the conditions matter as much as the conclusion. Age, time since menopause began, how much your symptoms are affecting you, and your personal health history all shape whether hormone therapy makes sense for you. That's a conversation, not a rule you apply to yourself.

The questions to bring to your visit

Before your appointment, write down your age, roughly when your periods became irregular or stopped, and the symptoms bothering you most, with how often they happen. Then add any personal history of breast cancer, endometrial cancer, blood clots, stroke or heart disease.

Then ask your provider 3 things. Do I fall inside the group the Menopause Society's statement describes? Which product and form are you considering, and what does its current label say? How will we check in on how it's working and how I'm feeling?

If you're still in perimenopause, with periods that come and go, say so. Mayo Clinic notes the transition often begins sometime in your 40s, and your stage of the transition is part of the picture.

A better starting point, not a shortcut

The label changes give you and your provider a more current place to start. They don't replace the parts of the decision that are about you: your symptoms, your history and what you want from treatment. At Elevate, every women's hormone consult starts with a full panel and a one-on-one conversation with a provider, because those are the parts no label can answer.

The warning you remember was rewritten. The questions that matter most are still yours to ask.